益肾活血法对冠心病心绞痛肾虚血瘀证内皮功能及抗氧化作用的影响
|
摘要
目的：观察益肾活血法对冠心病心绞痛肾虚血瘀证患者的症状改善及其治疗前后一氧化氮(NO)、内皮素(ET)、超氧化物歧化酶(SOD)指标的变化,同时说明对其干预冠心病内皮功能及抗氧化作用,评价益肾活血方治疗冠心病心绞痛的临床疗效、对内皮功能的影响及抗氧化作用。
方法：采用随机对照的临床试验方案进行研究。选择2009年4月—2010年2月期间在江苏省中医院心内科住院病人中符合纳入冠心病心绞痛诊断标准及中医肾虚血瘀证患者共50例,按照1：1的比例随机分成治疗组和对照组,在给予西药治疗的基础上,治疗组加用益肾活血方治疗,疗程为4周。观察治疗前后中医症候及ET、NO、SOD的变化。
结果：中医症候：两组中医证候积分均有明显改善(P<0.05),治疗组改善程度明显优于对照组(P<0.01)。中医症候临床疗效方面治疗组总有效率为96%,明显优于对照组的68%,两组具有显著性差异(P<0.05)。
NO、ET变化：治疗组NO水平较治疗前升高,ET水平下降,两者均有显著性差异(P<0.01)。组间比较治疗后的治疗组NO水平升高优于对照组,有统计学差异(P<0.05)；治疗后的治疗组ET水平下降优于对照组,有显著统计学差异(P<0.01)。
SOD变化：治疗组治疗后SOD水平明显升高(P<0.01),对照组治疗后SOD稍升高(P=0.34)；组间比较治疗后治疗组SOD水平升高明显优于对照组,有显著统计学差异(P<0.01)；且两组治疗前后差值比较有显著性差异(P<0.01)。
结论：益肾活血方能有效改善冠心病患者的临床症状,中医证候积分改善方面明显优于单纯西药对照组,有较好的临床疗效。益肾活血方明显下调ET水平,上调NO、SOD水平,表明益肾活血方能改善血管内皮功能,提高机体抗氧化能力,延缓动脉粥样硬化的进展。
Objective:To observe clinical effect of the principle of Supplementing Kidney and Activating Blood on ameliorating the clinical symptoms of kidney deficiency and blood stasis of Coronary Heart Disease(CHD)-angina pectoris and the changes of nitric oxide (NO),endotheli(ET),superoxide dismutase(SOD) before and after the treatment. To illustate the intervention of the principle of Supplementing Kidney and Activating Blood in coronary endothelial function and antioxidant, and evaluate its clinical effect on CHD-angina pectoris, endothelial function and antioxidant activity.
Methods:A randomized single-blind controlled clinical trial is adopted.50 patients were choosed who conform to the CHD-angina pectoris standard and TCM syndrome of kidney deficiency and blood stasis from the heart internal medicine department in JiangSu Province Traditional Chinese medicine hospital during April,2008 to February,2010.According to the ratio of 1:1 composition, the patients were randomly divided into the treatment group and the control group.The treatment group was treated with Supplementing Kidney and Activating Blood Prescription beside the western medicine. The paitients were treated 4 weeks as one treatment course. Observe the changes of Chinses symptoms and ET, NO,and SOD before and after the treatment.
Results:TCM syndrome:symptom score in both groups were significantly improved(P <0.05),the treatment group improved significantly better than the control group (P<0.01). The total effective rate of Chinese symptoms was 96%,which was significantly higher than that of the control group(68%).There was significant difference between the two groups (P<0.05).
NO, ET:NO level in treatment group increased after treatment, and ET level decreased, both of which were significant difference(P<0.01).Between the two groups after treatment, the increase of NO level in the treatment group was higher than that of the control group, and there was statistical difference (P<0.05);The decrease of ET level after treatment in the treatment group was more significant than that of the control group, and there was significant difference(P＜0.01).
SOD:SOD level was significantly higher after treatment in the treatment group(P<0.01), and in the control group it was slightly increased(P=0.34);Between the two groups after treatment, The increase of SOD level in treatment group was more significant than that of the control group, and there was significant difference (P<0.01);and the difference between the two groups before and after treatment were significant (P<0.01).
Conclusion: Supplementing Kidney and Activating Blood Prescription could effectively ameliorate the clinical symptoms of coronary heart disease, and the symptom score improvement was better than the control group,so it has good clinical efficacy.It could decrease the level of ET, increase the level of NO,SOD,which indicates that Supplementing Kidney and Activating Blood Prescription could improve endothelial function, improve antioxidant capacity, and delay the progress of atherosclerosis.
方法：采用随机对照的临床试验方案进行研究。选择2009年4月—2010年2月期间在江苏省中医院心内科住院病人中符合纳入冠心病心绞痛诊断标准及中医肾虚血瘀证患者共50例,按照1：1的比例随机分成治疗组和对照组,在给予西药治疗的基础上,治疗组加用益肾活血方治疗,疗程为4周。观察治疗前后中医症候及ET、NO、SOD的变化。
结果：中医症候：两组中医证候积分均有明显改善(P<0.05),治疗组改善程度明显优于对照组(P<0.01)。中医症候临床疗效方面治疗组总有效率为96%,明显优于对照组的68%,两组具有显著性差异(P<0.05)。
NO、ET变化：治疗组NO水平较治疗前升高,ET水平下降,两者均有显著性差异(P<0.01)。组间比较治疗后的治疗组NO水平升高优于对照组,有统计学差异(P<0.05)；治疗后的治疗组ET水平下降优于对照组,有显著统计学差异(P<0.01)。
SOD变化：治疗组治疗后SOD水平明显升高(P<0.01),对照组治疗后SOD稍升高(P=0.34)；组间比较治疗后治疗组SOD水平升高明显优于对照组,有显著统计学差异(P<0.01)；且两组治疗前后差值比较有显著性差异(P<0.01)。
结论：益肾活血方能有效改善冠心病患者的临床症状,中医证候积分改善方面明显优于单纯西药对照组,有较好的临床疗效。益肾活血方明显下调ET水平,上调NO、SOD水平,表明益肾活血方能改善血管内皮功能,提高机体抗氧化能力,延缓动脉粥样硬化的进展。
Objective:To observe clinical effect of the principle of Supplementing Kidney and Activating Blood on ameliorating the clinical symptoms of kidney deficiency and blood stasis of Coronary Heart Disease(CHD)-angina pectoris and the changes of nitric oxide (NO),endotheli(ET),superoxide dismutase(SOD) before and after the treatment. To illustate the intervention of the principle of Supplementing Kidney and Activating Blood in coronary endothelial function and antioxidant, and evaluate its clinical effect on CHD-angina pectoris, endothelial function and antioxidant activity.
Methods:A randomized single-blind controlled clinical trial is adopted.50 patients were choosed who conform to the CHD-angina pectoris standard and TCM syndrome of kidney deficiency and blood stasis from the heart internal medicine department in JiangSu Province Traditional Chinese medicine hospital during April,2008 to February,2010.According to the ratio of 1:1 composition, the patients were randomly divided into the treatment group and the control group.The treatment group was treated with Supplementing Kidney and Activating Blood Prescription beside the western medicine. The paitients were treated 4 weeks as one treatment course. Observe the changes of Chinses symptoms and ET, NO,and SOD before and after the treatment.
Results:TCM syndrome:symptom score in both groups were significantly improved(P <0.05),the treatment group improved significantly better than the control group (P<0.01). The total effective rate of Chinese symptoms was 96%,which was significantly higher than that of the control group(68%).There was significant difference between the two groups (P<0.05).
NO, ET:NO level in treatment group increased after treatment, and ET level decreased, both of which were significant difference(P<0.01).Between the two groups after treatment, the increase of NO level in the treatment group was higher than that of the control group, and there was statistical difference (P<0.05);The decrease of ET level after treatment in the treatment group was more significant than that of the control group, and there was significant difference(P＜0.01).
SOD:SOD level was significantly higher after treatment in the treatment group(P<0.01), and in the control group it was slightly increased(P=0.34);Between the two groups after treatment, The increase of SOD level in treatment group was more significant than that of the control group, and there was significant difference (P<0.01);and the difference between the two groups before and after treatment were significant (P<0.01).
Conclusion: Supplementing Kidney and Activating Blood Prescription could effectively ameliorate the clinical symptoms of coronary heart disease, and the symptom score improvement was better than the control group,so it has good clinical efficacy.It could decrease the level of ET, increase the level of NO,SOD,which indicates that Supplementing Kidney and Activating Blood Prescription could improve endothelial function, improve antioxidant capacity, and delay the progress of atherosclerosis.
引文
[1]叶任高.内科学[M]．北京：人民卫生出版社,2005：264-273.
[2]卫生部心血管病防治研究中心中国心血管病报2005[M]．北京：中国大百科出版社,2006.
[3]林谦.冠心病(胸痹心痛)的病因病机及辨证论治[J].中国临床医生,2000,28(10)11-14.
[4]于涛,曹洪欣.胸痹(冠心病)病机演变探微[J].中医药信息,2004,21(2)：1-2.
[5]刘德恒,等.冠心病心绞痛395例中医证型特点探讨[J].中医杂志,1995，36(10)：617-618.
[6]路志正.调理脾胃法在胸痹治疗中的运用[J].中国中医急症,1999,8(5)：298.
[7]徐风芹.陈可冀治疗自发型心绞痛经验[J].中医杂志,2001,42(1)：16.
[8]罗耀文.胸痹心痛临床几个问题的探讨[J].四川中医,1988(2)：8.
[9]廖子君,等.冠心病从肝论治[J].新中医,1994,4(7)：9.
[10]赵益业,林晓忠,张敏州,等.邓铁涛教授以心脾相关学说诊治冠心病经验介绍[J].新中医,2007,39(4)：5-6.
[11]宋雅芳,姬爱冬,徐升.杨培君治疗心血管疾病经验撷菁[J].辽宁中医杂志,2006,33(9)：1072.
[12]胡世云,范武庆.瘀毒阻络与冠心病证治[J].湖南中医药导报,2002,8(2)：49-53.
[13]王道瑞.试论秦伯未先生的学术经验[J].黑龙江中医药,1988,(1)：1-4.
[14]岳美中.心痛、胸痹的探讨[J].新中医,1974,(4)：8-13.
[15]林功铮.曹惕寅论治心绞痛[J].辽宁中医杂志,1983,(6)：5-7.
[16]郑学农,李银忠,李树军.论冠心病从肾施治[J].辽宁中医药大学学报.2009,11(11)：57-58.
[17]王晓才,农一兵,林谦,等.冠心病中医证候与冠心病发病的相关性研究[J].北京中医药大学学报(中医临床版),2007,3：4-6.
[18]丁邦晗,吕强,张敏州.胸痹心痛的中医危险证型[J].中国中医急症,2004,13(5)：298-300.
[19]李秋恒.益肾通心丸治疗冠心病心绞痛临床观察[J].中国中医急症,2004,13(8)：491-492.
[20]蒋梅先.张伯臾以补法治疗老年冠心病的经验[J].上海中医药杂志,1989,(5)：6-9.
[21]焦增绵.冠心病从肾论治六法[J].浙江中医杂志,1989,24(12)：536.
[22]杨焕斌,林坚,罗陆一.补肾法对冠心病心绞痛患者NO、NOS、ET的影响[J].中国中医药信息,2006,13(1)：18-19.
[23]朱明军.孙建芝教授从肝论治冠心病经验[J].河南中医,2003,23(1),20-21.
[24]于志强.冠心病从肝论治[J].辽宁中医学院学报,2002,2(3)：161-162.
[25]冯天.从肝论治胸痹[J].云南中医杂志,1993,14(4)：38-39.
[26]杨森.冠心病心绞痛从肝论治体会[J].河南中医,2005,25(1)：47.
[27]陈锋.冠心病从肺论治初探[J].辽宁中医杂志,1990,(1)：8-9.
[28]张毅,范平.冠心病从肺论治探析[J].山东中医杂志,1998,17(6)：243-244.
[29]余秋平.李七一从脾胃论治冠心病8法[J].中医杂志,2004,45(5)：386-387.
[30]黄国荣,吴焕林.益气健脾化痰法对于冠心病患者血小板及血脂影响的临床研究[J].新中 医,2005,37(6)：28-29.
[31]张均华.血管内皮功能障碍与冠状动脉疾病[J].中华老年心脑血管病杂志,2002,4(1)：3.
[32]王海燕,胡大一等.内科学[M]．北京大学医学出版社,2005,338-341.
[33]李强,陈宇,孙婷婷.冠心病某些危险因素研究进展[J].吉林医学,2008,29(6)：446-447.
[34]龚洪涛,杜凤和.幽门螺杆菌感染对冠心病患者内皮功能及血清同型半胱氨酸的影响[J].中国全科医学,2009,12(8B)：1536-1537.
[35]Romano CarratelliC,Nuzzo I,Cozzolino D,et al Relationship between Chlamydia pneumoniae infection. Inflammatory markers and coronary heart diseases[J].Int.Immunopharm aco,2006,6:848.
[36]王洪海,乔伯英,张小平,等.人血清C应蛋白(CRP)的测定及其在临床上的应用[J].中国实验临床免疫学杂志,1990,2(2)：1-2.
[37]Anderson J L,Carlquist J F,Muhlestein J B,et al. Eval-uation of C-reactive protein,an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial.infarction. JAmColl Cardiol,1998,32:35-41.
[38]Lindmark E,Wallemin L,Siegbahn A. Blood cell activation,coagulation,and inflammation inmen andwomenwith coronary artery disease[J].Thromb Res,2001,103(3):249.
[39]Geisel J,Hennen B, HubnerU,et al The impact of hyperhottocysteinem ia as a cardiovascular risk factor in the prediction of coronary heart disease [J].Clin Chem Lab Med,2003,410(1):1513.
[40]Ubbink J B,The prevalence of homocysteine and hypercholesterolemia in angio Graphically defined Cor-onary heart disease[J],KlinWochenschr,1991,69(12):527-534.
[41]Niskanen LK,Laaksonen DE,NyyssonenK,et al Uric acid level as a risk factor for cardiovascular and all-causemortality in middle-aged men:a prospective cohort study[J].Arch Intern Med,2004,164(14):1546
[42]刘存芬.血清尿酸胆红素及血浆纤维蛋白原与冠心病关系探讨[J].检验医学与临床,2010,7(2)：134-135.
[43]IshizakaN,Crendling kk. Heme oxygenase-1 is regulated by angiotensin II in rat vascular smooth muscle cells[J].Hypertension,1997,29(3):912.
[44]Wu TW,FungKP,Wu J,et al Antioxidation ofhuman low density lipoprotein by unconjugated bilitubins[J]. Biochem Pharmaco,1996,51(6):859.
[45]张慧芳,张晶梅.血清总胆红素与冠心病相关性研究[J].中国误诊学杂志,2010,10(5)：1033.
[46]Cersosimo E,DeFronzoRA.Insulin resistance and endothelial dysfunction:the road map to cardiovascular diseases[J].Diabetes Metab ResRev,2006,22(6):423-436.
[47]Libby P,RidkerPM,MaseriAInflammation.inather.osclerosis[J].Circulation,2002,105(9):1135-1143.
[48]孙锡印,杨雯琳,冠心病气滞血瘀与气虚血瘀证型间血载脂蛋白的异同及辨治影响[J].江苏中医,1997,18(6)：40-41.
[49]CaiH,Harrison DG.Endothelial dysfunction in cardiovascular diseases:the role of oxidant stress[J].Circ Res,2000,87(10):840-844.
[50]Matsuura E,KobayashiK,TabuchiM,etal. Oxidativemodification of low density lipoprotein and immune regulation of atherosclerosis[J].ProgLipid Res,2006,45(6):466-486.
[51]Esper RJ,Vilari-no JO,Machado RA,et al. Endothelial dysfunction in normal and abnormal glucose metabolism[J]. Adv Cardiol,2008,45:17-43.
[52]Wennmalm A Nitric oxide(NO) in the cardiovascular system:role in atherosclerosis and hypercholesterolemia Blood Press,1994,3(5):279-282.
[53]Levine GN,Vita JA Cholesterol reduction in cardiovascular disease:Clinical benefits and possible mechanisms N Engl J Med,1995,332 (8):512-521.
[54]方玉强,黄岚．内皮脂酶与动脉粥样硬化的关系及意义[J].心脏杂志,2009,21(6)：872-874.
[55]李贵星,刘双凤.动脉粥样硬化发病机制的研究进展[J].中国实验诊断学,2007,11(9)：1268-1271.
[56]杨光华.病理学[M].第五版.北京：人民卫生出版社,2001：122-126.
[57]Gouni-Berthold I,Sachinidis A.possible non-classic intracellμlar and molecμlar mechanism of LDL cholesterol action contributing to the development and progression of atherosclerosis[J].Currvasc pharmacol,2004,2(4):363-70.
[58]Gudnason V.Lipoprotein(a):a causal independent risk factor for coronary heart disease[J]Curr Opin Cardiol,2009,24(5):490-495.
[59]MountPF,LaneN,Venkatesan S,etal.Bradykinin stimulates endothelial cell fatty acid oxidation by CaMKK dependent activation of AMPK[J].Atherosclerosis,2008,200(1):28-36.
[60]Ross R.pathogenesis of atheroscleroeis:a perepective for the,1990s[J].Nature,1993.362:801-809.
[61]李娟,高怀林,贾振华,等.中医药保护血管内皮功能的研究进展[J].辽宁中医杂志,2009,36(12)：2196-2200.
[62]Mombouli JV,Vanhoutte PM.Endothelial dysfunction:from physiology to therapy[J].Cell Cardiol,1999, 31:61-74.
[63]王红,张向阳.血管内皮功能障碍的研究进展[J].新疆医科大学学报2005,28(2)：180-182.
[64]Ramesh KV.Ashok shenoy K.Endothelial:Many ways to correct-trends that promise[J].Indian Joural of pharmacology,2003,35:73-82.
[65]Celermajer DS,Sorensen KE,Bull C,et al Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction.J Am Coll Cardiol,1994,24(6): 1468-1474.
[66]周新民.血管内皮功能及检测方法[J].内科,2008,3(2)：265-267.
[67]Nathan C.Points of control in inflammation[J].Nature,2002,420(9):846-852.
[68]郭晔炳,柳景华.血管内皮功能的检测及临床意义[J].心肺血管病杂志,2009,29(6)：443-446.
[69]安英华,张建军.促血管新生治疗和冠心病[J].心肺血管病杂志,2005,24(2)：128-129.
[70]Wassmann S,Werner N,Czech T,et al.Improvement of endothelial function by systemic transfusion of vascularprogenitor cells. Circ Res,2006,99:E74-83.
[71]Heiss C,Keymel S,Niesler U,et al.Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol,2005,45:1441-1448.
[72]Assmus B,Urbich C,Aicher A, et al HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes.Circ Res,2003,92: 1049-1055.
[73]Celermajer DS,Sorensen KE.Gooch VM,et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.Lancet,1992,340:1111-1115.
[74]Gori T,Dragone S,Lisi M,et al. Conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function. J Am Coll Cardiol,2008,51:1953-1958.
[75]ellien J,Joannides R,IacobM,et al.Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol, 2006,290:H1347-52.
[76]Spieker LE, Luscher TF, Noll G.ETA receptors mediate vasoconstriction of large conduit arteries during reduced flow in humans.J Cardiovasc Pharmacol,2003,42:315-318.
[77]黄晓波,刘伊丽,查道刚.静脉心肌声学造影早期检测冠脉微血管内皮功能障碍的实验研究[J].中国超声医学杂志,2002,18(5)：321-323.
[78]Doucette JW,Corl PD,PayneHM,et al Validation of a Doppler guide for intravascular of coronary artery flow vel-ocity[J].Circulation,1992,85(12):1899-1911.
[79]邓右斌,黎春蕾,朱蔚,等.冷加压试验超声心动图评价高血压病患者的冠脉内皮功能[J].中国超声医学杂志,2000,16(6)：423-425.
[80]冯立刚.通心络胶囊对冠心病患者血管内皮功能的影响[J].中原医刊,2005：32(19)：64.
[81]张秋雁,苏剑峰,周小青,等.桃仁、红花不同配比的血府逐淤汤对大鼠急性心肌缺血的保护作用[J].中西医结合心脑血管病杂志,2004,2(11)：649.
[82]李卫青,谢梦洲,魏平,等.复方丹参滴丸对缺血性心脏病患者血浆NO、ET及血流变的影响.山西中医,2000,16(4)：25-27.
[83]王保申,刘革命,周建合.下瘀血汤对冠心病心绞痛患者血浆内皮素及血栓素B2的影响[J].吉林中医药,2006,26(4)：38.
[84]崔俊彪,吴素铭,徐秋连等.黄芪对冠心病患者PBMC凋亡及血浆ET、IL-6的影响[J].中国厂矿医学2006,19(3)：264.
[85]张振贤,江艳芬,符德玉.益气养阴、活血解毒法对冠心病患者血管内皮损伤、血小板活化及炎症因子的影响[J].中医杂志,2008,49(4)：317-319.
[86]张育彬.生脉注射液对老年冠心病不稳定型心绞痛NO、VEGF及hs-CRP的影响[J].长春中医药大学学报,2007,23(5)：39-40.
[87]蔡冬梅,殷胜利,吴伟康,等.补阳还五汤治疗气虚血淤型冠心病的临床疗效及血浆NO含量的改变[J].现代医学,2004,32(1)：25.
[88]刘洪,李荣亨.复原胶囊对气虚血瘀证冠心病血液TXB2、6-Keto-PGF1a、NO、ROS的干预作用及相 关机制研究[J].中国老年学杂志,2006,11(6)：1484-1485.
[89]郑峰,谢荣芳,褚剑锋,等.冠心生脉饮对冠心病心绞痛患者血清VEGF与NO的影响[J].福建中医学院学报,2006,16(4)：17-18.
[90]冼绍祥,黄鹤,刘小虹,等.益气、行气活血法在冠心病心血瘀阻证中的治疗作用研究[J].新中医,2001,33(4)：14-16.
[91]王健,杨关林.化瘀祛痰颗粒剂对冠心病患者血管内皮功能的影响[J].辽宁中医杂志,2005,32(5)：430.
[92]赵华云,黄洁玲,秦鉴.化湿汤对冠心病患者血浆心钠素、内皮素和血脂的影响及临床观察[J].湖北中医学院学报,2001,13(1)：28-29.
[93]王永.通脉汤对冠心病心绞痛患者ET及NO的影响[J].长春中医药大学学报,2007,23(2)：52.
[94]罗陆一,刘增印.心气虚患者红细胞超氧化物歧化酶及血清过氧化脂质含量变化[J].中医研究,1993,6(1)：26-27.
[95]杨永祥,洪秀芳.冠心病血瘀证患者血小板脂质过氧化物与血栓素A2前列环素平衡的研究[J].中国中西医结合杂志,1993,13(11)：661-662.
[96]张华,梁慕筠.补阳还五汤治疗冠心病的临床研究及其作用机制探讨[J].中国中西医结合杂志,1995,15(4)：213-215.
[97]李树青,贺宏.黄芪对冠心病心绞痛病人血清SOD和LPO的作用[J].中西医结合心脑血管病杂志,2003,1(1)：23-24.
[98]陈江斌,许家,王利,等.三七总皂苷对冠心病患者过氧化脂质及纤维蛋白溶酶原激活物的影响[J].中国新药杂志,2000,9(11)：781-782.
[99]夏城东,殷惠军,等.他汀类药物改善内皮功能的多效应研究进展[J].心血管病学进展,2008,29(6)：956-959.
[100]刘丽芳,卢海刚.钙拮抗剂与血管内皮功能障碍.实用心脑肺血管病杂志[J],2005,13(5)：312-314.
[101]Chen L Preservation of endogenous antioxidant activity and inhibition or lipid peroxidation as common mechanisms of antiatherosclerotic effects vitamin E Lovastatin and amlodipine JAm CollCardiol,1997, (2):569-575.
[102]徐济民.改善血管内皮功能的降压药研究进展[J].社区卫生保健,2008,7(4)：302-304.
[103]陈国雄,卜军,张存泰,等.卡维地洛与阿替洛尔对急性冠状动脉综合征患者血管内皮功能及可溶性细胞间粘附分子的影响[J].中国综合临床,2005,21(12)：1057-1059.
[104]Yin WH,Chen JW,Tsai C,etal.L-arfinine improves endothelial function and reducesLDL oxidation in patients with stable coronary artery disease[J]Clin Nutr,2005,24(6):988-997.
[105]刘国英,改善血管内皮功能防治冠心病研究进展[J].心血管病学进展,2006,27卷增刊：39-41.
[106]吴源,高东梅,等.曲美他嗪对冠心病患者血管内皮功能的改善作用[J].吉林大学学报(医学版),2009,35(4)：685-688.
[107]陶寿淇.缺血性心脏病的命名及诊断标准[J].中华心血管杂志,1981,9(1)：75-76.
[108]石磊.冠心病症状分析指导中医辨证分型客观化[J].现代中西医结合杂志,2008,31(17)：4815- 4816.
[109]郭光,高克颜.活血通脉汤治疗冠心病心绞痛(心血瘀阻型)62例[J]．中医研究,2004,17(1)：28-29.
[110]陈松苍,王耀华.黄精口服液对剧烈运动小鼠氧自由基代谢及肌酸激酶影响[J].中医研究,1996,9(4)：6-8.
[111]夏晓凯,张庭廷,陈传平.黄精多糖的体外抗氧化作用研究[J].湖南中医杂志,2007,22(4)：90-96.
[112]丁安荣等.黄精等六种补益中药对小鼠红细胞膜Na+-K+-ATP酶活性的影响[J].中成药,1990,12(9)：28.
[113]于莉,李恒昌,黄国辉,等.淫羊藿治疗冠心病140例临床疗效观察[J].上海中医药杂志,1989,(8)：26-27.
[114]黄秀兰,王伟,张雪静,等.淫羊藿总黄酮注射液对H202诱导心肌细胞损伤的影响[J].北京中医药大学学报,2006,29(6)：404-407.
[115]周群,汪晓云,蔺承艳,等.红花注射液对冠心病患者血小板、凝血及纤溶功能的影响[J].中国综合临床,2002,18(10)：888-889.
[116]李翠芳.红花注射液对心绞痛患者氧自由基的影响[J].现代中西医结合杂志,2005,14(1)：25-26.
[117]侯亚利,李桢,李宝亮,等.红花注射液对冠心病患者血液流变学指标及自由基的影响[J].中医临床康复,2004,8(33)：7450-7451.
[118]李霁,王阶,何庆勇等.三七总皂苷在冠心病中的研究进展[J].时珍国医国药,2008,19(1)：22-23.
[119]陈江斌,许家琍,江洪,等.三七总皂苷对冠心病患者过氧化脂质及纤维蛋白溶酶原激活物的影响[J].中国新药杂志,2000,9(11)：781-782.
[120]Huang YS,Yang ZC,Yan BQet al Improvement of early postbum cardiac function by use of Panax notoginseng and immediate total eschar excision in one operation [J].Burns,1999,25:35.
[2]卫生部心血管病防治研究中心中国心血管病报2005[M]．北京：中国大百科出版社,2006.
[3]林谦.冠心病(胸痹心痛)的病因病机及辨证论治[J].中国临床医生,2000,28(10)11-14.
[4]于涛,曹洪欣.胸痹(冠心病)病机演变探微[J].中医药信息,2004,21(2)：1-2.
[5]刘德恒,等.冠心病心绞痛395例中医证型特点探讨[J].中医杂志,1995，36(10)：617-618.
[6]路志正.调理脾胃法在胸痹治疗中的运用[J].中国中医急症,1999,8(5)：298.
[7]徐风芹.陈可冀治疗自发型心绞痛经验[J].中医杂志,2001,42(1)：16.
[8]罗耀文.胸痹心痛临床几个问题的探讨[J].四川中医,1988(2)：8.
[9]廖子君,等.冠心病从肝论治[J].新中医,1994,4(7)：9.
[10]赵益业,林晓忠,张敏州,等.邓铁涛教授以心脾相关学说诊治冠心病经验介绍[J].新中医,2007,39(4)：5-6.
[11]宋雅芳,姬爱冬,徐升.杨培君治疗心血管疾病经验撷菁[J].辽宁中医杂志,2006,33(9)：1072.
[12]胡世云,范武庆.瘀毒阻络与冠心病证治[J].湖南中医药导报,2002,8(2)：49-53.
[13]王道瑞.试论秦伯未先生的学术经验[J].黑龙江中医药,1988,(1)：1-4.
[14]岳美中.心痛、胸痹的探讨[J].新中医,1974,(4)：8-13.
[15]林功铮.曹惕寅论治心绞痛[J].辽宁中医杂志,1983,(6)：5-7.
[16]郑学农,李银忠,李树军.论冠心病从肾施治[J].辽宁中医药大学学报.2009,11(11)：57-58.
[17]王晓才,农一兵,林谦,等.冠心病中医证候与冠心病发病的相关性研究[J].北京中医药大学学报(中医临床版),2007,3：4-6.
[18]丁邦晗,吕强,张敏州.胸痹心痛的中医危险证型[J].中国中医急症,2004,13(5)：298-300.
[19]李秋恒.益肾通心丸治疗冠心病心绞痛临床观察[J].中国中医急症,2004,13(8)：491-492.
[20]蒋梅先.张伯臾以补法治疗老年冠心病的经验[J].上海中医药杂志,1989,(5)：6-9.
[21]焦增绵.冠心病从肾论治六法[J].浙江中医杂志,1989,24(12)：536.
[22]杨焕斌,林坚,罗陆一.补肾法对冠心病心绞痛患者NO、NOS、ET的影响[J].中国中医药信息,2006,13(1)：18-19.
[23]朱明军.孙建芝教授从肝论治冠心病经验[J].河南中医,2003,23(1),20-21.
[24]于志强.冠心病从肝论治[J].辽宁中医学院学报,2002,2(3)：161-162.
[25]冯天.从肝论治胸痹[J].云南中医杂志,1993,14(4)：38-39.
[26]杨森.冠心病心绞痛从肝论治体会[J].河南中医,2005,25(1)：47.
[27]陈锋.冠心病从肺论治初探[J].辽宁中医杂志,1990,(1)：8-9.
[28]张毅,范平.冠心病从肺论治探析[J].山东中医杂志,1998,17(6)：243-244.
[29]余秋平.李七一从脾胃论治冠心病8法[J].中医杂志,2004,45(5)：386-387.
[30]黄国荣,吴焕林.益气健脾化痰法对于冠心病患者血小板及血脂影响的临床研究[J].新中 医,2005,37(6)：28-29.
[31]张均华.血管内皮功能障碍与冠状动脉疾病[J].中华老年心脑血管病杂志,2002,4(1)：3.
[32]王海燕,胡大一等.内科学[M]．北京大学医学出版社,2005,338-341.
[33]李强,陈宇,孙婷婷.冠心病某些危险因素研究进展[J].吉林医学,2008,29(6)：446-447.
[34]龚洪涛,杜凤和.幽门螺杆菌感染对冠心病患者内皮功能及血清同型半胱氨酸的影响[J].中国全科医学,2009,12(8B)：1536-1537.
[35]Romano CarratelliC,Nuzzo I,Cozzolino D,et al Relationship between Chlamydia pneumoniae infection. Inflammatory markers and coronary heart diseases[J].Int.Immunopharm aco,2006,6:848.
[36]王洪海,乔伯英,张小平,等.人血清C应蛋白(CRP)的测定及其在临床上的应用[J].中国实验临床免疫学杂志,1990,2(2)：1-2.
[37]Anderson J L,Carlquist J F,Muhlestein J B,et al. Eval-uation of C-reactive protein,an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial.infarction. JAmColl Cardiol,1998,32:35-41.
[38]Lindmark E,Wallemin L,Siegbahn A. Blood cell activation,coagulation,and inflammation inmen andwomenwith coronary artery disease[J].Thromb Res,2001,103(3):249.
[39]Geisel J,Hennen B, HubnerU,et al The impact of hyperhottocysteinem ia as a cardiovascular risk factor in the prediction of coronary heart disease [J].Clin Chem Lab Med,2003,410(1):1513.
[40]Ubbink J B,The prevalence of homocysteine and hypercholesterolemia in angio Graphically defined Cor-onary heart disease[J],KlinWochenschr,1991,69(12):527-534.
[41]Niskanen LK,Laaksonen DE,NyyssonenK,et al Uric acid level as a risk factor for cardiovascular and all-causemortality in middle-aged men:a prospective cohort study[J].Arch Intern Med,2004,164(14):1546
[42]刘存芬.血清尿酸胆红素及血浆纤维蛋白原与冠心病关系探讨[J].检验医学与临床,2010,7(2)：134-135.
[43]IshizakaN,Crendling kk. Heme oxygenase-1 is regulated by angiotensin II in rat vascular smooth muscle cells[J].Hypertension,1997,29(3):912.
[44]Wu TW,FungKP,Wu J,et al Antioxidation ofhuman low density lipoprotein by unconjugated bilitubins[J]. Biochem Pharmaco,1996,51(6):859.
[45]张慧芳,张晶梅.血清总胆红素与冠心病相关性研究[J].中国误诊学杂志,2010,10(5)：1033.
[46]Cersosimo E,DeFronzoRA.Insulin resistance and endothelial dysfunction:the road map to cardiovascular diseases[J].Diabetes Metab ResRev,2006,22(6):423-436.
[47]Libby P,RidkerPM,MaseriAInflammation.inather.osclerosis[J].Circulation,2002,105(9):1135-1143.
[48]孙锡印,杨雯琳,冠心病气滞血瘀与气虚血瘀证型间血载脂蛋白的异同及辨治影响[J].江苏中医,1997,18(6)：40-41.
[49]CaiH,Harrison DG.Endothelial dysfunction in cardiovascular diseases:the role of oxidant stress[J].Circ Res,2000,87(10):840-844.
[50]Matsuura E,KobayashiK,TabuchiM,etal. Oxidativemodification of low density lipoprotein and immune regulation of atherosclerosis[J].ProgLipid Res,2006,45(6):466-486.
[51]Esper RJ,Vilari-no JO,Machado RA,et al. Endothelial dysfunction in normal and abnormal glucose metabolism[J]. Adv Cardiol,2008,45:17-43.
[52]Wennmalm A Nitric oxide(NO) in the cardiovascular system:role in atherosclerosis and hypercholesterolemia Blood Press,1994,3(5):279-282.
[53]Levine GN,Vita JA Cholesterol reduction in cardiovascular disease:Clinical benefits and possible mechanisms N Engl J Med,1995,332 (8):512-521.
[54]方玉强,黄岚．内皮脂酶与动脉粥样硬化的关系及意义[J].心脏杂志,2009,21(6)：872-874.
[55]李贵星,刘双凤.动脉粥样硬化发病机制的研究进展[J].中国实验诊断学,2007,11(9)：1268-1271.
[56]杨光华.病理学[M].第五版.北京：人民卫生出版社,2001：122-126.
[57]Gouni-Berthold I,Sachinidis A.possible non-classic intracellμlar and molecμlar mechanism of LDL cholesterol action contributing to the development and progression of atherosclerosis[J].Currvasc pharmacol,2004,2(4):363-70.
[58]Gudnason V.Lipoprotein(a):a causal independent risk factor for coronary heart disease[J]Curr Opin Cardiol,2009,24(5):490-495.
[59]MountPF,LaneN,Venkatesan S,etal.Bradykinin stimulates endothelial cell fatty acid oxidation by CaMKK dependent activation of AMPK[J].Atherosclerosis,2008,200(1):28-36.
[60]Ross R.pathogenesis of atheroscleroeis:a perepective for the,1990s[J].Nature,1993.362:801-809.
[61]李娟,高怀林,贾振华,等.中医药保护血管内皮功能的研究进展[J].辽宁中医杂志,2009,36(12)：2196-2200.
[62]Mombouli JV,Vanhoutte PM.Endothelial dysfunction:from physiology to therapy[J].Cell Cardiol,1999, 31:61-74.
[63]王红,张向阳.血管内皮功能障碍的研究进展[J].新疆医科大学学报2005,28(2)：180-182.
[64]Ramesh KV.Ashok shenoy K.Endothelial:Many ways to correct-trends that promise[J].Indian Joural of pharmacology,2003,35:73-82.
[65]Celermajer DS,Sorensen KE,Bull C,et al Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction.J Am Coll Cardiol,1994,24(6): 1468-1474.
[66]周新民.血管内皮功能及检测方法[J].内科,2008,3(2)：265-267.
[67]Nathan C.Points of control in inflammation[J].Nature,2002,420(9):846-852.
[68]郭晔炳,柳景华.血管内皮功能的检测及临床意义[J].心肺血管病杂志,2009,29(6)：443-446.
[69]安英华,张建军.促血管新生治疗和冠心病[J].心肺血管病杂志,2005,24(2)：128-129.
[70]Wassmann S,Werner N,Czech T,et al.Improvement of endothelial function by systemic transfusion of vascularprogenitor cells. Circ Res,2006,99:E74-83.
[71]Heiss C,Keymel S,Niesler U,et al.Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol,2005,45:1441-1448.
[72]Assmus B,Urbich C,Aicher A, et al HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes.Circ Res,2003,92: 1049-1055.
[73]Celermajer DS,Sorensen KE.Gooch VM,et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.Lancet,1992,340:1111-1115.
[74]Gori T,Dragone S,Lisi M,et al. Conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function. J Am Coll Cardiol,2008,51:1953-1958.
[75]ellien J,Joannides R,IacobM,et al.Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol, 2006,290:H1347-52.
[76]Spieker LE, Luscher TF, Noll G.ETA receptors mediate vasoconstriction of large conduit arteries during reduced flow in humans.J Cardiovasc Pharmacol,2003,42:315-318.
[77]黄晓波,刘伊丽,查道刚.静脉心肌声学造影早期检测冠脉微血管内皮功能障碍的实验研究[J].中国超声医学杂志,2002,18(5)：321-323.
[78]Doucette JW,Corl PD,PayneHM,et al Validation of a Doppler guide for intravascular of coronary artery flow vel-ocity[J].Circulation,1992,85(12):1899-1911.
[79]邓右斌,黎春蕾,朱蔚,等.冷加压试验超声心动图评价高血压病患者的冠脉内皮功能[J].中国超声医学杂志,2000,16(6)：423-425.
[80]冯立刚.通心络胶囊对冠心病患者血管内皮功能的影响[J].中原医刊,2005：32(19)：64.
[81]张秋雁,苏剑峰,周小青,等.桃仁、红花不同配比的血府逐淤汤对大鼠急性心肌缺血的保护作用[J].中西医结合心脑血管病杂志,2004,2(11)：649.
[82]李卫青,谢梦洲,魏平,等.复方丹参滴丸对缺血性心脏病患者血浆NO、ET及血流变的影响.山西中医,2000,16(4)：25-27.
[83]王保申,刘革命,周建合.下瘀血汤对冠心病心绞痛患者血浆内皮素及血栓素B2的影响[J].吉林中医药,2006,26(4)：38.
[84]崔俊彪,吴素铭,徐秋连等.黄芪对冠心病患者PBMC凋亡及血浆ET、IL-6的影响[J].中国厂矿医学2006,19(3)：264.
[85]张振贤,江艳芬,符德玉.益气养阴、活血解毒法对冠心病患者血管内皮损伤、血小板活化及炎症因子的影响[J].中医杂志,2008,49(4)：317-319.
[86]张育彬.生脉注射液对老年冠心病不稳定型心绞痛NO、VEGF及hs-CRP的影响[J].长春中医药大学学报,2007,23(5)：39-40.
[87]蔡冬梅,殷胜利,吴伟康,等.补阳还五汤治疗气虚血淤型冠心病的临床疗效及血浆NO含量的改变[J].现代医学,2004,32(1)：25.
[88]刘洪,李荣亨.复原胶囊对气虚血瘀证冠心病血液TXB2、6-Keto-PGF1a、NO、ROS的干预作用及相 关机制研究[J].中国老年学杂志,2006,11(6)：1484-1485.
[89]郑峰,谢荣芳,褚剑锋,等.冠心生脉饮对冠心病心绞痛患者血清VEGF与NO的影响[J].福建中医学院学报,2006,16(4)：17-18.
[90]冼绍祥,黄鹤,刘小虹,等.益气、行气活血法在冠心病心血瘀阻证中的治疗作用研究[J].新中医,2001,33(4)：14-16.
[91]王健,杨关林.化瘀祛痰颗粒剂对冠心病患者血管内皮功能的影响[J].辽宁中医杂志,2005,32(5)：430.
[92]赵华云,黄洁玲,秦鉴.化湿汤对冠心病患者血浆心钠素、内皮素和血脂的影响及临床观察[J].湖北中医学院学报,2001,13(1)：28-29.
[93]王永.通脉汤对冠心病心绞痛患者ET及NO的影响[J].长春中医药大学学报,2007,23(2)：52.
[94]罗陆一,刘增印.心气虚患者红细胞超氧化物歧化酶及血清过氧化脂质含量变化[J].中医研究,1993,6(1)：26-27.
[95]杨永祥,洪秀芳.冠心病血瘀证患者血小板脂质过氧化物与血栓素A2前列环素平衡的研究[J].中国中西医结合杂志,1993,13(11)：661-662.
[96]张华,梁慕筠.补阳还五汤治疗冠心病的临床研究及其作用机制探讨[J].中国中西医结合杂志,1995,15(4)：213-215.
[97]李树青,贺宏.黄芪对冠心病心绞痛病人血清SOD和LPO的作用[J].中西医结合心脑血管病杂志,2003,1(1)：23-24.
[98]陈江斌,许家,王利,等.三七总皂苷对冠心病患者过氧化脂质及纤维蛋白溶酶原激活物的影响[J].中国新药杂志,2000,9(11)：781-782.
[99]夏城东,殷惠军,等.他汀类药物改善内皮功能的多效应研究进展[J].心血管病学进展,2008,29(6)：956-959.
[100]刘丽芳,卢海刚.钙拮抗剂与血管内皮功能障碍.实用心脑肺血管病杂志[J],2005,13(5)：312-314.
[101]Chen L Preservation of endogenous antioxidant activity and inhibition or lipid peroxidation as common mechanisms of antiatherosclerotic effects vitamin E Lovastatin and amlodipine JAm CollCardiol,1997, (2):569-575.
[102]徐济民.改善血管内皮功能的降压药研究进展[J].社区卫生保健,2008,7(4)：302-304.
[103]陈国雄,卜军,张存泰,等.卡维地洛与阿替洛尔对急性冠状动脉综合征患者血管内皮功能及可溶性细胞间粘附分子的影响[J].中国综合临床,2005,21(12)：1057-1059.
[104]Yin WH,Chen JW,Tsai C,etal.L-arfinine improves endothelial function and reducesLDL oxidation in patients with stable coronary artery disease[J]Clin Nutr,2005,24(6):988-997.
[105]刘国英,改善血管内皮功能防治冠心病研究进展[J].心血管病学进展,2006,27卷增刊：39-41.
[106]吴源,高东梅,等.曲美他嗪对冠心病患者血管内皮功能的改善作用[J].吉林大学学报(医学版),2009,35(4)：685-688.
[107]陶寿淇.缺血性心脏病的命名及诊断标准[J].中华心血管杂志,1981,9(1)：75-76.
[108]石磊.冠心病症状分析指导中医辨证分型客观化[J].现代中西医结合杂志,2008,31(17)：4815- 4816.
[109]郭光,高克颜.活血通脉汤治疗冠心病心绞痛(心血瘀阻型)62例[J]．中医研究,2004,17(1)：28-29.
[110]陈松苍,王耀华.黄精口服液对剧烈运动小鼠氧自由基代谢及肌酸激酶影响[J].中医研究,1996,9(4)：6-8.
[111]夏晓凯,张庭廷,陈传平.黄精多糖的体外抗氧化作用研究[J].湖南中医杂志,2007,22(4)：90-96.
[112]丁安荣等.黄精等六种补益中药对小鼠红细胞膜Na+-K+-ATP酶活性的影响[J].中成药,1990,12(9)：28.
[113]于莉,李恒昌,黄国辉,等.淫羊藿治疗冠心病140例临床疗效观察[J].上海中医药杂志,1989,(8)：26-27.
[114]黄秀兰,王伟,张雪静,等.淫羊藿总黄酮注射液对H202诱导心肌细胞损伤的影响[J].北京中医药大学学报,2006,29(6)：404-407.
[115]周群,汪晓云,蔺承艳,等.红花注射液对冠心病患者血小板、凝血及纤溶功能的影响[J].中国综合临床,2002,18(10)：888-889.
[116]李翠芳.红花注射液对心绞痛患者氧自由基的影响[J].现代中西医结合杂志,2005,14(1)：25-26.
[117]侯亚利,李桢,李宝亮,等.红花注射液对冠心病患者血液流变学指标及自由基的影响[J].中医临床康复,2004,8(33)：7450-7451.
[118]李霁,王阶,何庆勇等.三七总皂苷在冠心病中的研究进展[J].时珍国医国药,2008,19(1)：22-23.
[119]陈江斌,许家琍,江洪,等.三七总皂苷对冠心病患者过氧化脂质及纤维蛋白溶酶原激活物的影响[J].中国新药杂志,2000,9(11)：781-782.
[120]Huang YS,Yang ZC,Yan BQet al Improvement of early postbum cardiac function by use of Panax notoginseng and immediate total eschar excision in one operation [J].Burns,1999,25:35.